Nachrichten zur OKYO PHARMA LTD Aktie

Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical…

OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company’s chief executive, Gary Jacob, is set…

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101)…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the…

OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to accelerate the clinical development of urcosimod, formerly called OK-101, to treat neuropathic…

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company’s recent developments, including the formal naming of…

OKYO Pharma Ltd (NASDAQ:OKYO) said on Monday that its experimental drug urcosimod has demonstrated stability for over two and a…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has filed a Fast Track designation application with the US Food and Drug…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod."…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that its lead asset, OK-101, has been granted the United States Adopted Name (USAN) "urcosimod."…

OKYO Pharma Ltd (NASDAQ:OKYO) is uniquely positioned to emerge as a key player in the ocular treatment arena as it…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that its chief executive officer Gary Jacob has purchased 10,000 of the company’s shares at US$1.04…

OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for…

OKYO Pharma Ltd (NASDAQ:OKYO) has provided an update on its clinical programs along with the release of interim financial results for…

OKYO Pharma Ltd (NASDAQ:OKYO) has announced the receipt of $1.4 million in non-dilutive funding. The clinical-stage biopharmaceutical company is developing...…

OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference…

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company’s Phase 2 clinical trial…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational…

OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at…

OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101’s use…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman…

OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs…

OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in…

OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in…

OKYO Pharma Ltd (NASDAQ:OKYO) has shared encouraging results from a phase II trial of its treatment candidate for dry eye disease. The…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it is rescheduling its Key Opinion Leader event on the results of its Phase 2 trial…

OKYO Pharma Ltd (NASDAQ:OKYO) unveiled new results showing its lead drug OK-101 has shown significant and measurable improvements in various…

OKYO Pharma Ltd (NASDAQ:OKYO) has announced plans to host a Key Opinion Leader (KOL) event on April 9 following the…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it will be releasing new and comprehensive data from its Phase 2 trial of…